UK's Compass Pathways Q1 operating income beats estimates as expenses fall

Overview

• UK mental health biotech's Q1 operating income beat analyst expectations as expenses declined

• Company posted net income of $91.2 mln, driven by non-cash warrant revaluation gain

• Cash position rose to $466 mln, expected to fund operations into 2028

Outlook

• COMPASS Pathways expects final NDA submission for COMP360 in Q4 2026

• Company anticipates 26-week data from COMP006 trial in early Q3 2026

• COMPASS Pathways expects cash position to fund operations into 2028

Result Drivers

• WARRANT REVALUATION GAIN - Net income was primarily driven by a $130.9 mln non-cash gain on fair value adjustment related to warrants, as the fair value fluctuates with share price

• LOWER OPERATING EXPENSES - Research and development and general and administrative expenses declined due to lower clinical trial costs and reduced legal/professional fees

Company press release: ID:nBwKwkXca

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Compass Pathways PLC is $18.00, about 92.1% above its May 12 closing price of $9.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.